Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy
© 2021 International Society of Nephrology. Published by Elsevier Inc..
INTRODUCTION: Personalized treatment for patients with membranous nephropathy requires accurate prediction of the disease course at an early stage. In this study, we evaluated the value of baseline anti-phospholipase A2 receptor (PLA2R1) antibody titer as a prognostic biomarker in patients with PLA2R1-associated membranous nephropathy.
METHODS: In this cohort study, we included 168 patients (118 men, 50 women) referred to our nephrology center between February 1995 and November 2016. Mean age was 52 ± 13 years. There were 156 patients with new-onset disease and 12 patients with a relapse (n = 10) or recent use of immunosuppressive therapy (n = 2). We measured anti-PLA2R1 titer at baseline and analyzed progression to severe disease (30% increase of serum creatinine or start of immunosuppressive therapy) as a primary study endpoint over 60 months.
RESULTS: There was a clear association between anti-PLA2R1 antibody titer and severity of the nephrotic syndrome. In univariate analysis, anti-PLA2R1 antibody titer was also associated with disease progression. However, in Cox proportional hazard models that included proteinuria and serum creatinine, anti-PLA2R1 antibody titer was no longer associated with clinical outcome. Results were similar when limiting the analysis to the patients with new-onset disease.
CONCLUSION: Our study questions the relevance of single measurement of anti-PLA2R1 antibodies at baseline as a prognostic biomarker in membranous nephropathy. Future studies are needed to determine the possible role of sequential measurements of anti-PLA2R1 antibodies as a prognostic biomarker of disease progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Kidney international reports - 6(2021), 6 vom: 04. Juni, Seite 1677-1686 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Logt, Anne-Els van de [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-PLA2R1 antibodies |
|---|
| Anmerkungen: |
Date Revised 24.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2021.04.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327163585 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327163585 | ||
| 003 | DE-627 | ||
| 005 | 20231225200151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2021.04.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327163585 | ||
| 035 | |a (NLM)34169209 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Logt, Anne-Els van de |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 International Society of Nephrology. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: Personalized treatment for patients with membranous nephropathy requires accurate prediction of the disease course at an early stage. In this study, we evaluated the value of baseline anti-phospholipase A2 receptor (PLA2R1) antibody titer as a prognostic biomarker in patients with PLA2R1-associated membranous nephropathy | ||
| 520 | |a METHODS: In this cohort study, we included 168 patients (118 men, 50 women) referred to our nephrology center between February 1995 and November 2016. Mean age was 52 ± 13 years. There were 156 patients with new-onset disease and 12 patients with a relapse (n = 10) or recent use of immunosuppressive therapy (n = 2). We measured anti-PLA2R1 titer at baseline and analyzed progression to severe disease (30% increase of serum creatinine or start of immunosuppressive therapy) as a primary study endpoint over 60 months | ||
| 520 | |a RESULTS: There was a clear association between anti-PLA2R1 antibody titer and severity of the nephrotic syndrome. In univariate analysis, anti-PLA2R1 antibody titer was also associated with disease progression. However, in Cox proportional hazard models that included proteinuria and serum creatinine, anti-PLA2R1 antibody titer was no longer associated with clinical outcome. Results were similar when limiting the analysis to the patients with new-onset disease | ||
| 520 | |a CONCLUSION: Our study questions the relevance of single measurement of anti-PLA2R1 antibodies at baseline as a prognostic biomarker in membranous nephropathy. Future studies are needed to determine the possible role of sequential measurements of anti-PLA2R1 antibodies as a prognostic biomarker of disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-PLA2R1 antibodies | |
| 650 | 4 | |a glomerulonephritis | |
| 650 | 4 | |a membranous nephropathy | |
| 700 | 1 | |a Justino, Joana |e verfasserin |4 aut | |
| 700 | 1 | |a Vink, Coralien H |e verfasserin |4 aut | |
| 700 | 1 | |a van den Brand, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Debiec, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Lambeau, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Wetzels, Jack F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 6(2021), 6 vom: 04. Juni, Seite 1677-1686 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:6 |g day:04 |g month:06 |g pages:1677-1686 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2021.04.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 6 |b 04 |c 06 |h 1677-1686 | ||